



Bal Pharma Limited

14.02.2023

The Manager-Listing Compliance
National Stock Exchange of India Ltd
Mumbai.

BSE Limited
Mumbai.

Dear Sir,

Sub: Revised Consolidated Financial Results.
Ref: Regulation 30 of SEBI(LODR) Regulations, 2015.

With reference to the above, In continuation of our submissions to the exchange on 06.02.2023 with respect to unaudited stand alone and consolidated financial results of the Company for the quarter ended 31.12.2022, we are now submitting to the exchanges revised consolidated financial results of the Company for the quarter and nine months ended 31.12.2022.

In the consolidated financial results submitted on 06.02.2023, figures for the 6 months ended 30.09.2022 was furnished as corresponding figures for previous quarter instead of furnishing figures for nine months ended 31.12.2021 as corresponding figures for previous year.

We request you to take the revised consolidated financial results on record.

For Bal Pharma Ltd

SHAILES
H SIROYA

Digitally signed by SHAILES H SIROYA
DN: cn=SHAILES H SIROYA, o=KARNATAKA, email=SHAILES.H.SIROYA@BALPHARMA.COM
c=IN, email=SHAILES.H.SIROYA@BALPHARMA.COM, serial=1111111111, version=3
SHAILES H SIROYA
2.5.4.0 - SHAILES H SIROYA, o=KARNATAKA, email=SHAILES.H.SIROYA@BALPHARMA.COM, cn=SHAILES H SIROYA
Date: 2023.02.14 15:58:45 +05'30'

Authorised Signatory.

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. :080-41570811 / 13 / 19 Fax : 41570820



BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099
CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2022

(₹ in Lakhs except EPS)

SI No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31-Dec-22 Unaudited	30 Sept 2022 Unaudited	31 Dec 2021 Unaudited	31-Dec-22 Unaudited	31-Dec-21 Unaudited	31 March 2022 Audited
	Income						
I	Revenue from operations	7,661.88	7,530.73	6,916.67	22,176.54	20,716.51	28,121.45
II	Other income	46.03	4.80	75.24	75.24	144.83	515.20
III	Total Income - (I)+(II)	7,707.91	7,535.53	6,991.91	22,251.78	20,861.34	28,636.65
	Expenses						
IV	a) Cost of materials consumed	4,041.66	4,531.95	4,451.45	12,852.57	12,286.01	16,399.27
	b) Purchase of Stock-in-trade	403.64	237.32	199.23	743.47	722.69	842.60
	c) Changes in inventories of finished goods, Stock-in-trade and work-in-progress	42.87	-576.13	(640.53)	-828.97	(818.05)	-489.45
	d) Employees benefits expenses	1,405.94	1,426.54	1,222.90	4,066.71	3,426.25	4,725.47
	e) Finance costs	310.98	285.51	235.72	833.34	795.41	1,040.53
	f) Depreciation and amortization expense	244.79	236.82	221.36	704.17	661.93	904.01
	g) Other expenses	1,152.62	1,333.62	1,061.66	3,646.80	3,096.63	4,295.78
	Total Expense - (IV)	7,602.50	7,475.62	6,751.79	22,018.08	20,170.86	27,718.40
V	Profit before Exceptional item and Tax (III-IV)	105.41	59.91	240.12	233.69	690.48	918.25
VI	Exceptional items	-	-	-	-	-	-
VII	Profit/ (Loss) before Tax (V-VI)	105.41	59.91	240.12	233.69	690.48	918.25
VIII	Less: Tax Expense						
	Current tax	77.25	108.28	187.89	274.70	362.31	447.86
	Tax adjustments relating to previous year	-	-	-	-	-	93.65
	Deferred tax charge/ (credit)	-31.00	-60.95	4.70	(141.20)	(23.58)	(193.76)
		46.25	47.32	192.59	133.50	338.73	347.75
IX	Net Profit for the period	59.16	12.58	47.53	100.19	351.78	570.49
	Profit / (Loss) attributable to :						
	- Equity holders of the parent company	57.49	11.41	63.95	97.13	364.08	561.15
	- Non controlling interest	1.66	1.17	-16.52	3.06	-12.33	9.34
X	Other Comprehensive Income(OCI)						
	- Items that may not be reclassified to Profit or loss	-	-	-	-	-	0.31
	- Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive income, net of Income Tax	-	-	0.00	0.00	0.00	0.32
XI	Total Comprehensive Income for the period (IX+X)	59.16	12.58	47.53	100.20	351.78	570.81
	Profit / (Loss) attributable to :						
	Equity holders of the parent company	57.49	11.41	63.95	97.13	364.08	561.47
	Non controlling interest	1.66	1.17	-16.52	3.06	-12.33	9.34
XII	Paid up Equity Share Capital (Face value ₹ 10 per share)	1,568.98	1,557.24	1,482.24	1,568.98	1,482.24	1,482.24
XIII	Other Equity						4,380.42
XIV	Earnings per share (Face value of ₹ 10 each)						
	Basic - in ₹	0.38	0.08	0.32	0.64	2.37	3.79
	Diluted - in ₹	0.38	0.08	0.32	0.64	2.37	3.79

Notes:

- The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 06 Feb 2023.
- The consolidated financial results has been prepared in accordance with the Companies(Indian Accounting Standards) Rules, 2015(IND AS), prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies to the extent applicable. The audited consolidated financial results relate to Balpharma Limited, its subsidiaries (together constitute 'the group'), Joint venture and Associates and are prepared by applying IND AS 110 - " Consolidate Financial Statements ", and IND AS 28 - " Investment in Associates & Joint ventures".
- The Group has not received any intimation or information with regard to its vendors registration as a Micro, Small and medium enterprises. Accordingly, the entire dues to vendors has been classified as payable to other than MSME.
- The figures for the quarter ended December 31, 2022 are the balancing figure between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.
- The Company has only one reportable segment namely 'Pharmaceuticals'.
- The Company has filed application with NCLT for merger of Golden Drugs Pvt Ltd , a wholly owned subsidiary of the Company.
- During the quarter under review, the Board has made the allotment of 117500 equity shares to the employees of the company pursuant to exercise of stock options.
- Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the period presentation.

Place: Bengaluru
Date: 06 Feb 2023

by the order of the Board
For Bal Pharma Limited

Shailesh Siroya
Managing Director

